1. Home
  2. |Insights
  3. |WMATA OIG Announces Partnership with the U.S. Department of Justice’s Procurement Collusion Strike Force

WMATA OIG Announces Partnership with the U.S. Department of Justice’s Procurement Collusion Strike Force

Client Alert | 1 min read | 02.20.20

On February 18, 2020, Washington Metropolitan Area Transit Authority (WMATA) Inspector General Geoffrey A. Cherrington announced a partnership between WMATA Office of Inspector General special agents and the Department of Justice’s Procurement Collusion Strike Force (PCSF).

This new law enforcement partnership underscores the PCSF’s willingness to team up with state and local agencies to aggressively pursue allegations of procurement fraud and prosecute any wrongdoing. It is important that government contractors of all sizes and in all industries ensure they have the appropriate antitrust protections in place, and that they conduct routine training for all employees involved in the procurement process.

WMATA recently launched a $15.5 billion capital improvement program at the beginning of FY 2020 with funding coming from state and local governments in D.C., Maryland, and Virginia, as well as federal grants. Through the program WMATA will purchase new railcars and buses and make other investments in infrastructure and equipment over the next ten years. These projects will provide many business opportunities for government contractors and they will also create a local area of focus for the WMATA-DOJ team.

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...